Repositioning Candidate Details

Candidate ID: R0839
Source ID: DB05642
Source Type: investigational
Compound Type: small molecule
Compound Name: DDP-225
Synonyms: --
Molecular Formula: C17H20ClFN4OS
SMILES: O.Cl.CC1=CC2=C(N=C(N=C2S1)N1CCNCC1)C1=CC=CC=C1F
Structure:
DrugBank Description: DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases. Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003.
CAS Number: 476148-82-0
Molecular Weight: 382.88
DrugBank Indication: Investigated for use/treatment in alzheimer's disease, depression, diarrhea, gastrointestinal diseases and disorders (miscellaneous), and irritable bowel syndrome (IBS).
DrugBank Pharmacology: --
DrugBank MoA: DDP225 is an orally-active compound that targets two key pathways that control the gastrointestinal (GI) system, thus giving it the potential to address multiple symptoms associated with IBS-d. DDP225 has a dual mechanism of action. It possesses both noradrenaline reuptake inhibition and 5-HT3 receptor antagonist properties.
Targets: 5-hydroxytryptamine receptor 3A; Sodium-dependent noradrenaline transporter
Inclusion Criteria: Indication associated